Our Mission: To develop an effective drug discovery platform for Alzheimer’s Disease 1 in 8 over the age of 65 has Alzheimer’s, and nearly half of people aged 85 and older have the disease. drug market, currently $5.4 billion in 2010, is estimated to be $14.3 billion in 2020. Centered on AD modeling in patient-derived cellsApplies patient genetic diversity at the beginning of drug discovery to increase odds of success in clinical trials.